Appsens is a medical technology company established in 2017. The company is headquartered in Lillesand and works closely with national health services and universities on the development of advanced medical equipment. Knowledge and competence about medical needs and technological advances are the main focus of the company. The company's employees have in-depth knowledge of cardiology, wireless sensor technology and advanced software. Together with Sørlandet Hospital HF, the University of Agder and a number of technology partners, Appsens has developed the innovative heart sensor ECG247. ECG247 is a medically certified sensor for continuous long-term monitoring of heart rhythm to detect heart rhythm disorders.<>
>Appsens is owned by the founders and private investors. The company is supported by Innovation Norway and the Research Council. Orkla is responsible for the European distribution of the company's products and services. The company is ISO13485 certified by Túv Rheinland according to current European regulations for manufacturers of medical devices.
Thomas Ramdahl is chairman of the board of AppSens AS. Ramdahl is a former CEO of Algeta and Bayer, and has a doctorate from the University of Oslo.
Anita Tunold is the managing director of Norway's leading private health provider Aleris helse, and has extensive experience in communication and management
Harald Moræus Hanssen is a private investor, owner and CEO of the investment company Uthalden AS. He has a master's degree in economics from the Norwegian School of Management.
Åge Nærdal is a cand. Pharm, communications consultant and former CEO of GSK Norway
Bjørn Breien is a private investor and owner of Bjørn Breien AS. He has many years of experience as a journalist and editor.
Lars Peder Fensli is CFO of Arendals Fossekompani. He has a master's degree in economics from the Norwegian School of Management.